AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Charles River Laboratories International, Inc.
Video analysis: CRL
All videosNo video analysis for this stock yet. Request one from our team.
News: CRL
Charles River Laboratories to Present at Morgan Stanley and Baird Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:Morgan Stanley 2
Charles River Laboratories to Present at Morgan Stanley and Baird Conferences
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Morgan Stanley and Baird Conferences.
Amundi Sells 360,913 Shares of Charles River Laboratories International, Inc. $CRL
Amundi trimmed its position in Charles River Laboratories International, Inc. (NYSE: CRL) by 46.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 412,402 shares of the medical research company's stock after selling 360,913 shares during the period.
Does iShares Pharma ETF Offer Superior Returns to Invesco's Equal Weight Healthcare Fund?
IHE's concentrated pharma holdings delivered 50% returns over one year, while RSPH's equal-weight healthcare approach generated 29%. Risk profiles differ sharply too.
Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) has successfully implemented its Endosafe® Cartridge Technology Automated Manufacturing Suite, a significant advancement in bacterial endotoxin testing cartridge production that expands in-process inspection and digital traceability, strengthens manufacturing controls and increases production capacity. Reaching full operational capacity in Q3 2026, the automated suite is a major investment in advanced.
Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Is This the Right Time to Add CRL Stock to Your Portfolio?
Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.
Contrasting Charles River Laboratories International (NYSE:CRL) and IB Acquisition (NASDAQ:IBAC)
Charles River Laboratories International (NYSE: CRL - Get Free Report) and IB Acquisition (NASDAQ: IBAC - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership. Earnings and Valuation This table compares
Similar companies
-
Qiagen N.V.
QGEN
·
New York Stock Exchange
Compare
-
Bio-Rad Laboratories, Inc.
BIO
·
New York Stock Exchange
Compare
-
Baxter International Inc.
BAX
·
New York Stock Exchange
Compare
-
Avantor, Inc.
AVTR
·
New York Stock Exchange
Compare
-
Revvity, Inc.
RVTY
·
New York Stock Exchange
Compare
-
Penumbra, Inc.
PEN
·
New York Stock Exchange
Compare